openPR Logo
Press release

Keloids Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | miRagen Therapeutics, Inc., Yuhan Corporation, FIRSTSTRING RESEARCH LIMITED, Juventas Therapeutics, Inc.

04-10-2019 12:43 PM CET | Health & Medicine

Press release from: Keloids Therapeutics -Pharma Proff

Keloids Therapeutics- Pipeline Analysis 2018, Clinical Trials

A keloid is characterized by abnormal proliferation of scar tissue which occurs at the site of cutaneous injuries. Acne scars, burns, scratches, ear piercing, chickenpox scars, surgical incision sites and vaccination sites are some of the major causes of keloids.

Download the sample report at: https://www.pharmaproff.com/request-sample/1015

The commonly occurring symptoms associated with keloids include pink or red scars, hard lumpy raised region and itchy skin patches. According to the American Osteopathic College of Dermatology (AOCD), an estimated 10% of people experience keloid scarring.

Get the detailed analysis at: https://www.pharmaproff.com/report/keloids-therapeutics-pipeline-analysis

People with dark pigmented skin, such as African-Americans, are more prone to keloids. They can be treated by using corticosteroid injections, moisturizing oils, laser treatments and radiation therapies which shrinks keloids.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1015

Companies, such as FirstString Research Inc., miRagen Therapeutics Inc., Yuhan Corporation, and Juventas Therapeutics Inc., are developing therapeutics for the treatment of keloids. For instance, FirstString Research Inc., a biopharmaceutical company, is developing Granexin gel for the treatment of post-surgical keloids.

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Keloids Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | miRagen Therapeutics, Inc., Yuhan Corporation, FIRSTSTRING RESEARCH LIMITED, Juventas Therapeutics, Inc. here

News-ID: 1697441 • Views: 374

More Releases for Pipeline

Gastroenteritis Therapeutics Pipeline Analysis 2018
Gastroenteritis, also known as infectious diarrhoea, is an inflammatory disease caused by bacteria, viruses, or parasites through contaminated food and water. Download the sample report at: https://www.pharmaproff.com/request-sample/1028 The disease can be symptomatized by vomiting, nausea, cramping, and diarrhoea. Dehydration, joint inflammation, conjunctivitis, salmonella infection, persistent diarrhoea syndrome, lactose intolerance, and irritable bowel syndrome are among the several complications associated with gastroenteritis. Get the detailed analysis at: https://www.pharmaproff.com/report/gastroenteritis-therapeutics-pipeline-analysis The treatment medications for the disease
Hyperalgesia Therapeutics- Pipeline Analysis 2018
Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia. Download the sample report @ https://www.pharmaproff.com/request-sample/1100 Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.
Autism-Pipeline Review H1 2018
ReportsWeb.com has announced the addition of the “Global Autism Market Size Status and Forecast 2018”, The report classifies the global Autism Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H1 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.Autism, also known as complex
Osteoarthritis-Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint
Hypotension (Cardiovascular) Pipeline Review H2, 2017 - Pharmaceutical Pipeline …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension Pipeline Review, H2 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is
Insomnia (Central Nervous System) pipeline landscape - Pipeline Review, H1 2017
Latest Pharmaceutical and Healthcare disease pipeline guide “Insomnia Pipeline Review H1” 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working. Report Highlights Global Markets Direct's